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ABSTRACT 
Dementia is a clinical diagnosis requiring new functional 
dependence on the basis of progressive cognitive decline. It 
is estimated that 1.3% of the entire UK population, or 7.1% of 
those aged 65 or over, have dementia. Applying these to 2013 
population estimates gives an estimated number of 19,765 
people living with dementia in Northern Ireland. The clinical 
syndrome of dementia can be due to a variety of underlying 
pathophysiological processes. The most common of these 
is Alzheimer’s disease (50-75%) followed by vascular 
dementia (20%), dementia with Lewy bodies (5%) and 
frontotemporal lobar dementia (5%). The clinical symptoms 
and pathophysiological processes of these diseases overlap 
significantly. Biomarkers to aid diagnosis and prognosis are 
emerging. Acetylcholinesterase inhibitors and memantine 
are the only medications currently licensed for the treatment 
of dementia. The nature of symptoms mean people with 
dementia are more dependent and vulnerable, both socially 
and in terms of physical and mental health, presenting 
evolving challenges to society and to our healthcare systems.
INTRODUCTION
Dementia is a clinical diagnosis requiring new functional 
dependence on the basis of progressive cognitive decline and 
representing, as its Latin origins suggest, a departure from 
previous mental functioning.
The incidence of dementia rises with age making it an 
increasingly common phenomenon within our aging 
population. The nature of symptoms mean people with 
dementia are more dependent and vulnerable, both socially 
and in terms of physical and mental health, presenting 
evolving challenges to society and to our healthcare systems. 
Despite the seemingly simple premise, the clinical diagnosis of 
dementia can be difficult with de novo functional impairment 
often obscured by physical frailty, comorbid psychiatric 
symptoms such as depression and a subtle but steady assuming 
of household responsibilities by spouses and family. Clinical 
and pathological criteria for the main dementia-causing 
diseases overlap significantly. The emergence of symptoms 
decades into the pathophysiological process hamper targeted 
disease therapy. A great number of research initiatives 
are underway to identify potential biomarkers of disease 
processes earlier. The association of both overt cognitive 
decline and underlying pathophysiological processes with 
normal aging complicate the process of identifying disease 
processes early within the spectrum of normal aging. 
Once the diagnosis is established, prognostic measures 
are required, and are still lacking, as disease trajectories 
between individuals can vary greatly. Globally, governments 
are recognising these challenges. Investment and research 
infrastructure are beginning to reflect the scale of the need. 
Drugs conferring symptomatic benefit are available and 
memory service structures exist to diagnose dementias and 
guide management. The personal impact of dementia on 
patients and families is also being increasingly recognised, 
with discussion in the media surrounding famous sufferers 
and dramatisations in literature and film. Herein we attempt 
to describe the current landscape of dementia.
EPIDEMIOLOGY AND SOCIO-ECONOMIC 
IMPLICATIONS
Dementia is often arbitrarily considered early (< 65yrs) 
or late-onset (> 65yrs), with the vast majority (>97%) of 
cases being of late-onset 1. Table 1 shows the most recent 
age-related prevalence estimates for dementia in the UK, 
which equate to 1.3% of the entire UK population or 7.1% of 
those aged 65 or over 2. Applying these to 2013 population 
estimates gives an estimated number of 19,765 people living 
Table 1 
Gender specific age-related prevalence (%) of dementia in 
the UK (estimates from Dementia UK 2014)
Age in years Female Male Total 
60 – 64 0.9 0.9 0.9
65 – 69 1.8 1.5 1.7
70 – 74 3.0 3.1 3.0
75 – 79 6.6 5.3 6.0
80 – 84 11.7 10.3 11.1
85 – 89 20.2 15.1 18.3
90 – 94 33.0 22.6 29.9
95+ 44.2 28.8 41.1
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with dementia in Northern Ireland 2. This compares to the 
12,811 people registered with the Quality and Outcomes 
Framework for Northern Ireland (NI) with a diagnosis of 
dementia in 2013-2014 (http://www.dhsspsni.gov.uk/index/
statistics/qof/qof-achievement/qof-lcg-13-14.htm). 
The age-related incidence of dementia in the UK is falling, 
presumably as a result of better public health measures 3, 
meaning the increasing absolute numbers of people with 
dementia are based on the shifting population demographic, 
the aging population.  Global estimates of a doubling in the 
dementia population every 20 years giving an estimated 
115 million people with dementia by 2050 were revised 
further upwards in 2013, to take account of the likely further 
increases in lower and middle income countries 4. 
Prognosis at the time of dementia diagnosis varies, with 
evidence that age at diagnosis, gender, comorbidities and 
disease severity can all affect life expectancy 5. Whilst 
methodological variations limit the usefulness of the data 
available, median life expectancy from the time of diagnosis 
has been shown to range from 3.2 to 6.6 years, and from 
3.3 to 11.7 years from dementia onset 5. Local research has 
suggested a median survival of 5.9 years from diagnosis 
(unpublished data).
Transition into residential care as a result of the functional 
impairments of dementia is a prospect that worries many 
patients and a reality that many families face. It was estimated 
last year that 69% of all those living in residential care within 
the UK suffer from dementia 2.
It is perhaps no surprise then that dementia is expensive. 
The updated estimated cost to the UK economy of £26.3 
billion per year published last year 2 took account of the role 
played by unpaid carers (£11.6 billion), social care costs were 
estimated at £10.3 billion and healthcare costs at £4.3 billion 
in comparison. 
CLINICAL DIAGNOSIS
The clinical syndrome of dementia, characterised by 
new functional dependence on the basis of progressive 
cognitive decline, can be due to a variety of underlying 
pathophysiological processes. The most common of these 
is Alzheimer’s disease (AD; 50-75%) followed by vascular 
dementia (VaD; 20%), dementia with Lewy bodies (DLB; 
5%) and frontotemporal lobar dementia (FTLD; 5%) (Figure 
1). The significant clinical and pathological overlap between 
these processes mean their relative frequencies are estimates 
at best 1,6. Less common causes (3%) include Huntingdon’s 
disease, Creutzfeldt-Jakob disease, HIV/AIDS and multiple 
sclerosis. We will first consider the clinical and then the 
pathological properties of these diseases. 
Cognitive impairments central to the diagnosis of dementia 
can be categorised into five main domains: memory; executive 
function; language; visuospatial abilities; personality and 
behaviour. As dementia, of any cause, progresses, cognitive 
impairments will broaden, involving more domains, and 
deepen, causing increased functional impairment. It can thus 
be difficult to distinguish dementias of different aetiologies 
in the later stages. In the early stages however the pattern 
of prominent symptoms can help identify the most likely 
underlying disease process. Clinical criteria exist for all 
the main dementia sub-types, the main features of which 
are outlined in Table 2 7-11. All criteria require a diagnosis 
of dementia and include the caveats that there should not 
be a symptom pattern more in keeping with another of the 
dementias and that cognitive impairments should not be 
better explained by a psychiatric illness. Neuropsychiatric 
symptoms should be sought. Depression can be a cause or 
effect of cognitive impairments and often features such as 
hallucinations and delusions will not be volunteered unless 
specific enquiries are made.
AD, the most common cause of dementia, typically presents 
with short-term memory deficits, manifesting for example 
as repetitive questioning. Impairment in at least one other 
cognitive domain is required for a diagnosis of probable 
dementia due to AD (ADD). Atypical presentations of ADD 
include behavioural or language deficits suggesting frontal 
variants or prominent early visuospatial problems suggesting 
posterior cortical atrophy. The most relevant feature of a 
presentation of VaD is the temporal association of cognitive 
deficits with stroke and evidence of cerebrovascular disease 
on examination and imaging. The Lewy body diseases 
comprise DLB and Parkinson’s disease (PD). Patients with 
DLB may go on to develop Parkinsonism. As a rule of thumb, 
if the emergence of dementia and physical PD symptoms 
are within one year the diagnosis is PD dementia (PDD), if 
cognitive symptoms predate physical symptoms and signs by 
more than one year the diagnosis is considered to be DLB. 
Early language or behavioural symptoms raise the prospect 
of FTLD. In the younger age groups, ie less than 65, the 
incidence of FTLD and ADD are almost equal, in contrast 
to the vastly lower incidence of FTLD in older age groups. 
The early symptoms of behavioural variant FTLD often raise 
the possibility of primary functional psychiatric diagnosis, 
complicating diagnosis.
It is relatively common to be presented with clinical 
Fig 1. Pie chart showing estimated frequencies of dementia-
causing disease processes
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scenarios that do not wholly and exclusively fulfil a single 
diagnostic criteria. Reflecting the concurrent accumulation of 
pathophysiological processes within the brain, symptoms can 
represent overlapping disease processes and mixed pictures 
can be said to occur, this is most commonly the case with 
ADD and VaD.
Many people present with objective cognitive symptoms that 
fall short of the requirements for a diagnosis of dementia. 
Criteria exist then for the diagnosis of mild cognitive 
impairment (MCI) 12,13. Creation of this diagnostic category 
has facilitated focused follow up demonstrating that 5-10% 
per year of those with MCI will progress to fulfill the 
diagnostic requirements of a dementia 14.  Such symptoms 
can also be due to psychiatric illness, drugs known to be 
deleterious to cognition or may be transient and regress 
spontaneously. As the use of biomarkers, outlined below, 
evolves, identification of those more likely to be in the 
prodromal stages of a dementia is improving, with some 
arguing that patients should be identified at the MCI stage as 
either prodromal dementia or not 15. For now the diagnostic 
bracket of MCI, whilst disputed, remains.
Other diagnostic criteria exist. In addition to the criteria set 
out by McKhann et al in 2011 7 an International Working 
Group has proposed diagnostic criteria for ADD intended 
for use primarily in research 15. The older Hachinski 16 and 
NINDS-AIREN 17 scales are still used to define VaD. The 5th 
edition of the Diagnostic and Statistical Manual of Mental 
Disorders published in 2013 by the American Psychiatric 
Association 18 has introduced the terms major and mild 
neurocognitive disorders, which equate to dementia and MCI. 
Their criteria for the various subtypes equate broadly with the 
pre-existing clinical criteria.
Diagnosis and differentiation of dementias requires careful 
history taking and examination. Both patient and collateral 
histories are needed to establish a new functional dependence 
and to explore the progressive cognitive impairments as 
well as neuropsychiatric symptoms. Physical examination is 
required to examine for focal neurological or extrapyramidal 
signs. Cognition will be assessed informally during the 
course of the consultation but formal testing is required, and 
facilitates longitudinal monitoring. A suggested framework 
for assessment of patients presenting with cognitive 
complaints is outlined in Table 3.
Probably the most widely recognised formal cognitive test is 
the Mini Mental State Examination (MMSE), first proposed 
in 1975 19. Whilst assertions of copyright have impacted 
on its use in recent years the MMSE has become well and 
widely established, and provides a common language for 
those fluent in its use. The Montreal Cognitive Assessment, 
originally developed as a test for MCI, and also marked 
out of 30, has expanded into the space created by MMSE 
apprehension (www.mocatest.org). The Addenbrooke’s 
Cognitive Examination-III (ACE-III) provides a more 
thorough assessment and marks are calculated for each 
domain, then tallied to give a total, out of 100 (http://www.
neura.edu.au/frontier/research/test-downloads/). A growing 
variety of scales exist, none of which is perfect. Inter and 
intra-rater reliability can limit use and all scales are reliant 
on premorbid educational abilities. The important thing is to 
become familiar with a scale, ensure its consistent use within 
a service, and use it to monitor progression.
Table 2 
Clinical diagnostic criteria for dementias
Disease ADD DLB Behavioural variant FTLD Primary progressive 
aphasia (FTLD)
VaD
Authors (year) McKhann et al 
(2011)
McKeith et al 
(2005)
Rascovsky et al (2011) Gorno-Tempini et al 
(2011)
Gorelick et al (2011)
Required 
symptoms
(Typical ADD)
Memory 
deficits
+ deficits in at 
least one 
other cognitive 
domain
(Central features)
Attentional deficits
Executive 
dysfuction
Visuospatial 
deficits
(Core features, 2/3)
Fluctuating 
cognition
Visual 
hallucinations
Parkinsonism
(Suggestive 
features)
REM sleep 
behavior disorder
Neuroleptic 
sensitivity
Positive DAT scan
Behavioural disinhibition
Apathy or inertia
Loss of sympathy or 
empathy
Perseverative, stereotyped 
or compulsive/ritualistic 
behavior
Hyperorality and dietary 
changes
Executive dysfunction with 
relative sparing of 
episodic memory and 
visuospatial skills
(3/6 required)
Language deficit most 
prominent symptom 
and accounts for 
functional decline
No prominent memory, 
visuospatial or 
behavioural problems
Clear temporal 
relationship between 
vascular event and 
onset of cognitive 
deficits 
Cognitive deficits 
independent of motor/
sensory sequelae of 
vascular event
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PATHOPHYSIOLOGY/ PATHOLOGICAL 
FEATURES
The disease processes underlying dementia are yet to be 
fully understood. With the (probable) exception of VaD, all 
involve a pathological accumulation of a native protein: in 
the case of AD it is the extracellular plaques of amyloid and 
the intracellular tangles of hyperphosphorylated tau; in DLB 
it is alpha-synuclein in the form of Lewy bodes; in FTLD 
several culprits have been identified including TDP-43 and 
the hallmark proteins of AD and DLB in a frontotemporal 
distribution. Examples of these lesions can be seen in Figures 
2-5. It is important to remember that evidence of these 
processes is also found post-mortem in people who did not 
exhibit cognitive impairments prior to death, and that these 
patterns are not mutually exclusive, existing concurrently as 
they often do 20. 
These pathological accumulations are associated with synapse 
and neuronal loss and atrophy which also demonstrate 
patterns in terms of distribution. Hippocampal atrophy within 
the medial temporal lobe for instance is associated with AD, 
in keeping with the early amnestic symptoms 21 
Genetic studies have contributed greatly to our knowledge 
of these disease processes. The observation that people with 
Down’s syndrome (trisomy 21) almost invariably develop 
AD, led to the discovery of the first of three autosomal 
dominant genes associated with early-onset ADD 22. Study 
of these genes, responsible for amyloid cleavage, have 
been integral to the understanding of pathological amyloid 
production. In contrast to the aberrant production of amyloid 
proteins implicated in early onset ADD, late-onset ADD 
(LOAD) is thought to be more to do with faulty clearance 
of amyloid from the brain. Apolipoprotein E 23 and, more 
recently, TREM-2 24,25 alleles have been identified as risk 
factors for LOAD. Their pathophysiological roles remain 
unclear: they are implicated in amyloid processing and 
neuroinflammation amongst other pathways. Neither are 
sufficient or requisite for LOAD and are therefore not tested 
for in routine clinical practice. Genome wide association 
studies in recent years have consistently identified several 
genes with significant but modest associations with LOAD26 
and examination of their relevant pathways, including 
immune response and inflammation, cell migration and lipid 
transport, have enhanced the evolving understanding of the 
ADD disease process.
These methods are being applied across the dementia 
spectrum and similar pathways are implicated in DLB, FTLD 
and VaD 27,28. FTLD in particular has myriad of increasingly 
recognized heritable components.
Animal models, often based on these predisposing genetic 
mutations, continue to provide basic science research 
opportunities. Improving chemistry techniques, such as 
proteomics and metabolomics are also being used to study 
the disease using human-derived samples such as blood and 
cerebrospinal fluids. 
BIOMARKERS 
The search for biomarkers further informs our understanding 
of these disease processes and offers the opportunity to 
identify them prior to symptom emergence. A biomarker has 
Table 3 
Suggested foci of assessment of patients with cognitive symptoms
History History from patient and informant
Change from baseline
Functional decline
Past medical history 
Drug history
Current home circumstances
Alcohol and smoking
Driving
Family history
Some specific examples: repetitive questioning; inability to navigate 
journeys and less familiar environments eg shopping centres, 
own children’s home; difficulty recognising previously familiar 
people; difficulty using new equipment eg new oven; word-finding 
difficulties; tendency to participate less in group conversations; less 
attention to personal hygiene/appearance; new short-temperedness 
with family
Progressing to: agitation in the evening; not recognising home as own
Specific safety concerns: problems in the kitchen; problems with 
cigarette disposal; wandering; handling of money
Physical 
examination
Extrapyramidal signs
Focal neurological deficit(s)
Ability to follow instructions
Pulse
Chest auscultation
Cognitive 
examination and 
associated scales
(52,53)
Formal cognitive testing (eg MMSE/ACEIII)
Geriatric Depression Scale (or alternative)
Activities of Daily Living Scale
Neuropsychiatric Inventory 
Neuropsychiatric Inventory includes delusions, hallucinations, 
agitation/aggression, apathy, disinhibition, sleep and appetite
Investigation Bloods 
CT brain (or MRI if appropriate)
ECG
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been defined as a ‘characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a 
therapeutic intervention 29. Research into ADD is currently 
the main focus and biomarkers are generally considered as 
representing the underlying AD process (evidence of amyloid 
and tau accumulation) or neurodegeneration (markers of 
synapse/neuronal loss or atrophy) 7,15. 
Low amyloid beta and high tau in cerebrospinal fluid (CSF) 
and high levels of intracerebral amyloid as measured by 
positron emission tomography (PET) scanning predict 
the subsequent development of ADD 30. The downstream 
markers of neurodegeneration - hippocampal atrophy on 
MRI and decreased uptake of a radiolabelled glucose tracer 
(18-fluorodeoxyglucose, FDG) as measured using PET 
scanning (FDG-PET) have also been shown to increase 
diagnostic accuracy when used to supplement clinical 
measures 30.
The occurrence of these pathophysiological processes in 
cognitively normal people, especially with increasing age, 
complicates the interpretation of these biomarkers. Several 
studies of cognitively normal patients are ongoing and a 
recently published cross sectional study of 985 participants 
showed that over the age of 85 more people had biomarker 
changes in keeping with ADD than did not 31. There are 
significant variations in neuroimaging techniques across 
centres and also in the sampling, handling and analysis 
of CSF 21,32,33. Worldwide research collaborations, such as 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
are in place to try and accelerate our understanding of the 
pathophysiological processes underlying dementia, and hence 
the interpretation of biomarker findings, in both cognitively 
normal and impaired participants. Global standardisation 
initiatives are also ongoing with regard to MRI and PET 
imaging and CSF amyloid and tau. Biomarkers are beginning 
to be used in clinical practice 34 but the likelihood, and benefit, 
of more widespread adoption is dependent on these issues 
being resolved. 
Fig 2. An immunohistochemical section taken through the cortex 
in a case of ADD. An antibody to Beta A4 amyloid is applied to 
the tissue and detects this antigen which in turn stains the antigen 
brown. 
This shows a dense deposition of amyloid throughout the cortex as 
dense core (DC) and diffuse (D)  plaques.
Fig 3. Neuronal tangles stained with an antibody to Tau (T)
Fig 4. A pigmented neuron from the substantia nigra. A single 
Lewy Body is present. This patient also had diffuse cortical Lewy 
bodies characteristic of Pure Lewy Body Dementia
Fig 5. A section from the hippocampal dentate fascia showing dot 
like deposition of ubiquitin. 
This is characteristic of Frontotemporal Lobar Dementia with 
Ubiquitinised inclusions (now called TDP). 
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INVESTIGATION
Initial investigation of patients presenting with cognitive 
impairment centres on the exclusion of reversible causes 
of cognitive impairment. The National Institute of Clinical 
Excellence (NICE) recommends blood tests (full blood 
picture, urea and electrolytes, calcium, glucose, liver 
function tests, thyroid function tests and vitamin B12 and 
folate) and structural brain imaging (preferably MRI but CT 
will suffice) 35. In addition to ruling out tumours, subdural 
haematomas, stroke and normal pressure hydrocephalus, CT, 
and to a greater extent MRI, can also provide information 
regarding chronic ischaemia, infarcts and focal atrophy. 
Functional imaging, such as single-photon emission computed 
tomography (SPECT) and FDG-PET are recommended to 
help differentiate between the dementia sub-types where 
appropriate. Figures 6&7 show normal compared to reduced 
uptake in keeping with ADD on FDG-PET. Dopamine 
transporter (DAT) scanning has shown high sensitivity and 
specificity for DLB and is the investigation of choice when 
trying to differentiate between DLB and other dementias 36.
RISK FACTORS
In tandem with the laboratory science methods outlined 
above, observational studies have informed our understanding 
of the risk factors for dementia, as well as the natural history 
and prognosis of the diseases. Age is the main risk factor for 
dementia. Established modifiable risk factors for dementia 
include: depression, diabetes, (midlife) hypertension, 
(midlife) obesity, smoking, alcohol abuse, high cholesterol, 
coronary heart disease, renal dysfunction, low unsaturated 
fat intake and inflammation 37. It has been argued that the 
decrease in age-related dementia incidence seen in the UK 
is due to better public health measures and thus amelioration 
of these factors 3. There is in addition increased focus on 
recognised protective factors such as: cognitive activity, 
physical activity, healthy dietary pattern and low/moderate 
alcohol intake 37.
MANAGEMENT – NON-PHARMACOLOGICAL 
Management will be guided by the nature and severity 
of the symptoms and any safety concerns. Vascular risk 
factors should be addressed. Patients and relatives should 
be offered information and explanations. The Public Health 
Agency (www.publichealth.hscni.net ) have developed a 
booklet ‘Communicating effectively with a person living 
with dementia’ available via their website. The Alzheimer’s 
Society have local offices and provide information and 
support (www.alzheimers.org.uk ). Patients and carers should 
be referred to a social worker if a carer’s assessment is felt 
appropriate and to facilitate access to services such as Day 
Centres and social services care provision. As a result of 
the NI Dementia Strategy  a navigation service for all those 
diagnosed with dementia is being established in all Trusts; this 
will ensure patients and carers have a consistent contact point 
throughout their journey. Moderate physical exercise should 
be encouraged where possible. No formal cognitive training 
services are currently being offered consistently though 
supportive evidence is emerging and may translate into 
service provision. Where appropriate patients can be referred 
to community mental health teams. Transition into residential 
care is influenced by social circumstances, dementia severity 
and the behavioural and psychological symptoms of dementia 
(BPSD) eg aggression. Non-pharmacological measures are 
recommended as first line therapy for BPSD but there is as 
yet no consensus regarding the most effective measures. All 
patients should be advised to inform the Driver & Vehicle 
Agency and their insurer of a diagnosis of dementia. If there 
are concerns regarding a patient’s ability to drive they should 
be advised to stop driving. Where patients lack capacity to 
manage their own affairs and assets a referral to the Office of 
Care and Protection (www.courtsni.govuk/en-GB/Services/
OCP/ ) may be warranted. A draft Mental Capacity Bill (NI) 
(working title) is due to be introduced to the NI Assembly 
this year having already been consulted upon. It is likely this 
will have significant impact on how healthcare decisions are 
made for people who lack capacity.   
People with dementia are frequently admitted acutely to 
hospital, most commonly following a fall, and it is estimated 
that up to one quarter of in patients in UK hospitals, at any one 
time, have dementia 38. This is important as caring for patients 
with dementia requires modification of communication, 
diagnostic and, at times, management approaches. Patients 
Fig 6.
Fig 7. 
Figures 6 and 7 show normal and reduced uptake on FDG-PET 
scanning respectively. The decreased uptake in the temporoparietal 
and precuneus (arrow) regions, typical of ADD, can be seen.
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may have difficulties articulating symptoms. Constipation 
and acute urinary retention for example should be actively 
sought out. Disorientation and agitation may develop and both 
environmental (eg clear signage and clocks) and attitudinal 
(eg repeated reassurance, clear explanations, good lighting, 
involvement of families) approaches can ameliorate this. 
Dysphagia is a common occurrence as dementia progresses 
and patients may require dietary modification and assistance 
at meal times. Dyspraxia can hinder personal care, with 
considerate assistance required. Patients with dementia 
are more likely to develop delirium which can further 
complicate care needs 39. Rehabilitation attempts can be 
hampered by cognitive impairments but dementia should not 
be a contraindication to rehabilitation as evidence for benefit 
exists. Discharge planning is required, often with inclusion 
of families. More than one third of patients with dementia 
admitted to hospital from their own homes will be discharged 
to an institutional setting 38. A scheme has been introduced to 
increase the understanding, and identification, of dementia 
within hospital settings (http://butterflyscheme.org.uk ). 
MANAGEMENT – PHARMACOLOGICAL 
Offending medications, in particular those with anti-
cholinergic properties should be reconsidered and stopped 
where possible. It is important to note that even over the 
counter medications can affect cognition 40. An association 
with benzodiazepines has been suggested by observational 
work and these too should be reconsidered 41.
Acetylcholinesterase inhibitors and memantine, an NMDA 
receptor antagonist, (Table 4) are the only medications 
currently licensed for the treatment of dementia. All three 
acetylcholinesterase inhibitors (AChEi) have a license and 
are recommended by NICE for the treatment of ADD with 
rivastigmine additionally approved for the treatment of PDD 
42,43. Memantine is approved for the treatment of moderate 
ADD where AChEi are contraindicated or not tolerated and 
as an adjunct to AChEi therapy in severe disease 43. Evidence 
exists to suggest a moderate improvement in cognitive 
function with these drugs 44,45. These drugs are not licensed for 
use in VaD. In clinical practice it can be difficult to distinguish 
whether there is an ADD component and these medications 
are often offered as a therapeutic trial. There is no evidence to 
support the use of AChEi or memantine in FTLD; 46,47 AChEi 
usually make symptoms of FTLD worse as the underlying 
pathological process is different to that of ADD.
Mild, moderate and severe disease severity categories are 
often used but are arbitrary by nature. As a rule of thumb 
NICE considers corresponding cut-offs by MMSE of 21-26, 
10-20 and less than 10 35 but in practice this is only a single 
facet of the assessment outlined in Table 3. 
AChEi therapy exerts its benefit by raising pathologically low 
levels of the neurotransmitter acetylcholine. Potential adverse 
events include risk of bradycardia and syncope, potential 
worsening of obstructive airways disease and gastrointestinal 
disturbance. Assessment should therefore include an ECG and 
chest auscultation, with severe sinus bradycardia or evidence 
of a significant cardiac conduction defect or significant 
audible wheeze all contraindications to AChEi therapy. The 
possibility of reduction in the dose of beta-blocker or rate-
limiting calcium channel blocker could be considered prior to 
initiation of an AChEi. An anti-emetic, usually domperidone, 
can be prescribed on an as required basis for the first few 
weeks to alleviate nausea.  The British National Formulary 
recommends nocte administration of donepezil but it is 
acceptable to take it in the morning. The decision to continue 
or terminate drug therapy, in the setting of inevitable cognitive 
decline, can be difficult. The DOMINO-AD 48 study showed 
that continuation of donepezil therapy, even in severe disease, 
was associated with significant cognitive benefit. 
Souvenaid is a food for special medical purposes with 
evidence for improved memory function in early ADD 49. It is 
not available on prescription and requires a recommendation 
from a healthcare professional.  
BPSD is an umbrella term for a variety of symptoms including 
apathy, agitation, disinhibition and sleep disturbance. These 
can be particularly distressing for carers and often precipitate 
admission to institutional care. Atypical antipsychotics are 
sometimes employed to combat BPSD but are associated with 
significant side effects including an increase in mortality and 
so should be carefully considered 50. Only risperidone has a 
license for the treatment of BPSD and short-term treatment 
(<6 weeks) is recommended 42. Depression is a common 
symptom (see the upcoming review in this Journal regarding 
diagnosis and treatment of depression).
Many pharmacological avenues are being explored in an 
effort to find new effective, safe drugs for dementia. Efforts 
Table 4 
Acetylcholinesterase inhibitors and memantine
Generic name Brand name Dosing schedule
Donepezil Aricept 5mg od, titrated up to 10mg od after 4 weeks if tolerated
Galantamine Reminyl XL preparation available for od administration, 8mg daily initially, 
titrating up by 8mg after 4 weeks if tolerated to maximum of 24mg od
Rivastigmine
Rivastigmine 
patch
Exelon 1.5mg bd titrating up by 1.5mg bd at intervals of at least 2 weeks; usual range 3-6mg bd
4.6mg/24 hours titrating up to 9.5mg/24 hours after 4 weeks if tolerated
Memantine Ebixa 5mg od, titrated up by 5mg per week to maximum dose 20mg od
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are hampered by the as yet incomplete understanding of 
the pathophysiological processes being targeted. Drugs 
targeting amyloid production and amyloid plaque clearance 
have failed on safety and efficacy grounds. Anti-tau agents 
are currently being studied. Apart from Souvenaid the much 
vaunted dietary supplements have yet to be supported by 
consistent evidence. Safety concerns are being addressed, and 
emerging pathophysiological insights exploited, by attempts 
to reposition existing drugs within the dementia field, for 
example metformin 51.
CONCLUSION
Significant advances have been made in our understanding 
of dementia in recent decades. Dementia presents laboratory, 
clinical, societal and economic challenges. Diagnosis 
remains clinical, supplemented by improving biomarkers. 
Dementia causing diseases overlap in their pathophysiology 
and phenotypes. The only licensed drugs to date provide 
symptomatic benefit. Disease-modifying drug development 
is reliant on early identification of disease processes prior to 
symptom emergence, where it is currently felt best therapeutic 
window exists. Both biomarker and drug development depend 
on better understanding of underlying pathophysiological 
processes. The wide-reaching benefits of improved public 
health measures have yielded a decrease in age-related 
incidence but the ongoing demographic shift means efforts 
on all fronts must be redoubled if we are to diagnose, treat, 
understand and care for those of us who develop dementia. 
The importance of dementia as a global priority is recognised 
in the declarations of the G8 Dementia Summit in 2013, 
committing the G8 nations to the improvement in the 
quality of life for people with dementia and their carers and 
identification of disease-modifying therapies by way of a 
co-ordinated and funded international research framework.
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